GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2022-09-26| Trials & Approvals

Daiichi Sankyo Wins Approval For Cancer Treatment in Japan

by Max Heirich
Share To

Daiichi Sankyo announced the approval of the EZHARMIA® (valemetostat tosilate) by the Japan Ministry of Health, Labor and Welfare (MHLW). EZHARMIA is a dual inhibitor treating patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATL). The basis of the approval for the cancer treatment was a Phase 2 Study evaluating the treatment’s efficacy and safety.

Related Article: CHMP Gives Kite’s Lymphoma Immunotherapy a Positive Opinion

The Dual Inhibitor of Cancer

Enhancer of zeste homolog 1(EZH1) and enhancer of zeste homolog 2 (EZH2) are enzymes in the polycomb protein complex. EZH1 mediates histone methylation, while EZH2 provides the instructions for making histone methylation. However, researchers have noted that these enzymes’ overexpression is coupled with certain types of cancer. Specifically, changes in EZH2 impair cells’ ability to divide properly. This results in prostate, breast, and other body parts cancerous tumors.

Recent studies have explored the possibility of using EZH2 inhibition as a cancer treatment. . Recently, Pfizer presented promising data for PF-06821497, a EZH2 inhibitor targeting small lung and prostate cancer. However, while Pfizer’s candidate is still in its first Phase, EZHARMIA already completed its Phase 2 trial

EZHARMIA received an Orphan Drug Designation (ODD) from the United States Food and Drug Administration (FDA) for the treatment of PTCL in December 2021. In addition, Japan’s MHLW gave the treatment the same designation in November 2021. However, the MHLW beat the FDA in granting EZHARMIA approval. 

Approved off the Back of a Phase 2 Trial

A Phase 2 trial evaluated the safety and efficacy of EZHARMIA as a daily monotherapy in patients with relapsed/refractory ATL previously treated with mogamulizumab. The primary endpoint was an objective response rate (ORR) assessed by an independent efficacy assessment committee. EZHARMIA achieved an ORR of 48%, meeting the assessment criteria.

On the approval, Wataru Takasaki, PhD, Executive Officer, Head of R&D Division in Japan at Daiichi Sankyo, said, “As the first dual inhibitor of EZH1 and EZH2 to receive regulatory approval anywhere in the world, EZHARMIA represents an important advancement in the treatment of patients with relapsed or refractory adult T-cell leukemia/lymphoma, who have very few options beyond intensive chemotherapy.”

It is currently unknown whether EZHARMIA will advance to a Phase 3 clinical trial. However, Japan’s approval for cancer treatment has doubtlessly strengthened Daiichi Sankyo’s case for eventual approval by other regulatory bodies. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
MediBuddy Partners with Japan’s ELECOM to Launch Smart Health IoT Devices in India
2025-02-05
JPM 2025 Looks at the Cell and Gene Therapy Landscape – Autoimmune, Cancer, and Chronic Diseases are Front and Center
2025-01-21
Cecile Richards’s Battle with Glioblastoma
2025-01-21
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top